ACE2 and Alzheimer disease: Microarray, Western blotting, Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) and immunostaining analyses have undoubtedly shown that the expression levels of ACE2 significantly increase in the brain tissues of human AD subjects when compared with healthy, not-demented controls and in close relationship with the severity of clinical dementia and different neuropathological parameters, including the density of dystrophic neurites, the Aβ plaques and NFT accumulation [113,114,115].